BJOG : an international journal of obstetrics and gynaecology · 2023
Successful Eisenmenger syndrome-targeted drug therapy in pregnant women: a case series and literature review.
ОбзорСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen W, Chen J, Peng M, Luo J, Chen Y, Qiu H, Li J
Аннотация
OBJECTIVE: To clarify the real-world outcomes in pregnant women with Eisenmenger syndrome (ES) in the new therapeutic era and provide a literature review.
DESIGN: Retrospective case and literature review.
SETTING: Tertiary referral hospital (The Second Xiangya Hospital of Central South University).
SAMPLE: Thirteen women with ES delivered between 2011 and 2021.
METHODS: Respective study and literature reviews.
MAIN OUTCOMES MEASURES: Maternal and neonatal mortality and morbidity.
RESULTS: 12/13 (92%) pregnant women were treated with targeted drugs. 9/13 (69%) of patients had heart failure, but no maternal deaths occurred. 12/13 (92%) of women chose caesarean delivery. One pregnant woman gave birth at 37+1 weeks, and the remaining 12 (92%) patients had preterm birth. 10/13 (77%) women gave birth to live infants, of which 9/10 (90%) were low birthweight infants with a mean birthweight of 1575 g. The infant mortality rate was 1/10 (10%). Cardiac functional class improved during pregnancy, probably due to therapy; 11/13 (85%) of the pregnant women were in cardiac functional level III/IV at admission and 12 (92%) were in cardiac functional class II/III at discharge. Our literature review identified 72 cases of pregnancy with ES from 11 studies, which were characterised by a low rate of targeted drug use (28%) and a high maternal mortality rate of 24% in the perinatal period.
CONCLUSION: Our case series and literature review suggest that targeted drugs may be key to improving maternal mortality in ES.
DESIGN: Retrospective case and literature review.
SETTING: Tertiary referral hospital (The Second Xiangya Hospital of Central South University).
SAMPLE: Thirteen women with ES delivered between 2011 and 2021.
METHODS: Respective study and literature reviews.
MAIN OUTCOMES MEASURES: Maternal and neonatal mortality and morbidity.
RESULTS: 12/13 (92%) pregnant women were treated with targeted drugs. 9/13 (69%) of patients had heart failure, but no maternal deaths occurred. 12/13 (92%) of women chose caesarean delivery. One pregnant woman gave birth at 37+1 weeks, and the remaining 12 (92%) patients had preterm birth. 10/13 (77%) women gave birth to live infants, of which 9/10 (90%) were low birthweight infants with a mean birthweight of 1575 g. The infant mortality rate was 1/10 (10%). Cardiac functional class improved during pregnancy, probably due to therapy; 11/13 (85%) of the pregnant women were in cardiac functional level III/IV at admission and 12 (92%) were in cardiac functional class II/III at discharge. Our literature review identified 72 cases of pregnancy with ES from 11 studies, which were characterised by a low rate of targeted drug use (28%) and a high maternal mortality rate of 24% in the perinatal period.
CONCLUSION: Our case series and literature review suggest that targeted drugs may be key to improving maternal mortality in ES.